UNIGE document Scientific Article
previous document  unige:46926  next document
add to browser collection
Title

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects

Authors
Sitbon, O
Petit, J
Iserin, L
Humbert, M
Gressin, V
Simonneau, G
Published in European Journal of Clinical Investigation. 2006, vol. 36 Suppl 3, p. 25-31
Abstract Bosentan is an effective first-line therapy in New York Heart Association (NYHA) III patients with idiopathic pulmonary arterial hypertension (PAH). Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD).
Keywords AdolescentAdultAntihypertensive Agents/administration & dosageChildDrug Therapy, CombinationExercise Test/methodsFemaleHeart Defects, Congenital/complications/physiopathologyHumansHypertension, Pulmonary/complications/drug therapy/physiopathologyMaleMiddle AgedProstaglandins, Synthetic/therapeutic usePulmonary Circulation/drug effectsRetrospective StudiesSulfonamides/administration & dosageTreatment OutcomeVascular Resistance/drug effectsWalking/physiology
Identifiers
PMID: 16919007
Full text
Article (Published version) (112 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group L'hypertension pulmonaire (pédiatrie) (228)
Citation
(ISO format)
SITBON, O et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. In: European Journal of Clinical Investigation, 2006, vol. 36 Suppl 3, p. 25-31. https://archive-ouverte.unige.ch/unige:46926

136 hits

0 download

Update

Deposited on : 2015-02-19

Export document
Format :
Citation style :